# Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

> **NCT00782106** · PHASE1,PHASE2 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 11 (actual)

## Conditions studied

- Primary Immunodeficiency Diseases (PID)

## Interventions

- **BIOLOGICAL:** Recombinant human hyaluronidase + immune globulin intravenous
- **BIOLOGICAL:** Recombinant human hyaluronidase + immune globulin intravenous

## Key facts

- **NCT ID:** NCT00782106
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12-04
- **Primary completion:** 2007-11-01
- **Final completion:** 2007-11-01
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2021-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00782106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00782106, "Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00782106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*